MENARINI is a fully integrated privately owned pharma company with a long and successful heritage in strategic partnering across the globe. We have a profound know-how stemming from our strong R&D capabilities in key therapeutic areas, coupled with our excellence in commercial execution and our powerful direct presence on a global basis.
Respiratory
Respiratory diseases are not and must not be diseases with no way out. Menarini's commitment in respiratory therapeutic area has strong roots and aim at improving the lives of people suffering from diseases such as COPD (Chronic Obstructive Pulmonary Disease) and asthma. Putting the needs of the patient first, our mission is to provide high quality, added-value therapeutic solutions to make their life easier and better. With our broad range of respiratory medicines we are committed to expanding access to the most comprehensive care to more people meeting their real needs
Bronchial asthma and Chronic Obstructive Pulmonary Disease (COPD) are obstructive pulmonary diseases that affected millions of people all over the world. Asthma is a serious global health problem with an estimated 300 million affected individuals. COPD is one of the major causes of chronic morbidity and mortality and one of the major public health problems worldwide. COPD is the fourth leading cause of death in the world and further increases in its prevalence and mortality can be predicted. Although asthma and COPD have many similarities, they also have many differences. They are two different diseases with differences in etiology, age at diagnosis, symptoms characteristics, treatment management and progression course.
